Cardi-Ay Description for Physicians

Cardiovascular disease is now one of the most important causes of mortality in the world and has increased in recent years. World Health Organization predicts that cardiovascular disease will be the leading cause of death worldwide by 2020. About 17.7 million people died in the world in 2015 due to cardiovascular diseases (premature deaths of under 70 years old, representing 31% of the world's total deaths in that year).

Cardi-Ay herbal distilled is a combination of 17 different medicinal plants: Aloysia triphlla, Citrus aurantium, Echium amoenum, Melissa officinalis, Lavandula stoechas Valeriana officinalis, Viola odorata, Cinnamomum zelanic, Matricaria chamomilla, Rosa damascene, Malva sylvestris, Terminalia chebula, Rosa canina, Phoenix Dactylifera, Citrus medica, Pimpinella anisum and Salix alba. All of them have therapeutic effects in reducing blood lipids and deposits lipids in the vessels of the heart, blood purification and regulation of blood pressure. Each ml of Cardi-Ay contains valerat, citronella, limonene, violet, anthocyanin, Sallicin, Linalylacetat, Linalool and cinnamaldehyde, gallic acid, carotenoids, Quercetin, Tannine and Malvidin-3- glucoside (It should be noted that this component is an essential component of these plants that is effective in the treatment of cardiovascular diseases).

Applications of this herbal distilled are following:
Preventing arterial cramps, purification of blood from sediment and waste, adjustment of blood concentration, reduce blood lipids, reduce high blood pressure and reduced complications of atherosclerosis.

The invention with No. 94506 was registered on 27.12.2018 as a syrup of 17 medicinal plants (Cardi-Ay) to treat cardiovascular problems.

This product on 23.01.2018 with No. 56532 by the letter of the Department of Technology, Ferdowsi University of Mashhad, after scientific validation (with the feature of being new, being innovative, and the applicability of the mentioned items, in the field of technical knowledge and procurement method) is approved.

The early stages of the clinical tests were conducted in a pilot experiment. For this purpose the product was used as a supplement in the diet of patients. So, repeatedly checked the positive effects of the product on patients with cardiovascular problems. The results have shown that in 80% of the people who were considered as clinical community, taking this diet disrupted the symptoms of the disease. The minimum performance of this product for other people has been to prevent the progression of cardiovascular disease.

The usage of this product is 80-100 ml per day and 2 hours before lunch. The best time to use it at the height of thirst (the thirstier patient can absorb the product more). It should be noted that the duration of using Cardi-Ay and achieve a complete result depends on the duration of the person's diseases, the presence or absence of other diseases, the age of the patient, the degree of observance and the extent of the disease. In general, for a moderate level of diseases, the period is one month. This product is not recommended for people with constipation.

Pharmacological effects of Cardi-Ay (17 medicinal plants)

Preventing Myocardial Infarction

Blockage or narrowing of the vessels is one of the most important causes of heart attack. The most important measures to prevent heart attacks are vasodilation.

Cardi-Ay contains folic acid, due to the presence of plants such as Citrus medica, Citrus aurantium, and Aloysia triphlla, which prevents the stinging of the veins and the occurrence of heart attacks. Also, the folic acid found in Cardi-Ay is one of the B group vitamins, which reduces the substance called homocysteine in the blood.

The compounds in Cardi-Ay can exert vascular expansional effects in the presence of acetylcholine and decrease the contractile response to vasoconstrictive factors, which is done through changes in the synthesis and release of vascular prostaglandins (Grande, 2004). Cardi-Ay, with its effect on the smooth muscles of the vascular walls, causes vasodilatation of the peripheral arteries. It seems that this product, with open potassium channels, causes hyperplasia of the membrane potential and vasodilatation of the vessels. This product contains sulfur compounds and antioxidants that reduce the amount of fats in the vascular walls and dilation of the veins and improve the blood flow. As a result, blood flows easily between tissues and cells. As a result, blood flows easily between tissues and cells. The plants used in Cardi-Ay contain significant amounts of alpha linoleic acid and mega-3. These essential fatty acids help clear the blocked veins and prevent the fat from becoming hardened.

Diabetes and cardiovascular disease

Diabetes is one of the most important metabolic problems that a massive population of the world is experiencing. The number of people with diabetes in the world by the year 2050 is estimated to be around 300 million. Cardiovascular disease is known to be the main cause of 80% of deaths in diabetic people (Voulgari, 2010).

Diabetes can develop cardiac hypertrophy and can make the heart susceptible to ischemic injuries and ultimately increase the risk of impotence or heart attack (Hayat, 2004). Diabetes mellitus is clinically one of the most important risk factors for some other disorders such as nephropathy, retinopathy, neuropathy, cardiovascular disease. Different mechanisms are involved in disrupting blood vessel building in patients with diabetes. The vascular endothelium capacity is low in vascular vasodilator synthesis, such as prostatic acyclovir and nitric oxide, and vascular sprays such as endothelin are produced a lot. Given the effects mentioned in the cardioprotective effect of vasodilatation, this product is effective in treating this disorder caused by diabetes. The results of studies show that in diabetes, glucose metabolism disorders and protein glycosylation produce free oxygen radicals (Kumar, 2008). Cardi-Ay decreases malondialdehyde and significantly increases the antioxidant potential of the heart tissue in diabetic patients (Tripathi, 2009; Kumar, 2008). Cinnamomum decreases malondialdehyde and significantly increases the antioxidant potential of the heart tissue in diabetic patients (Khan et al., 2003). This substance is a flavonoid that increases the glucose oxidation. It also prevents the formation of free oxygen radicals. On the other hand, cinnamon increases the consumption of glucose and the production of glycogen and increases the phosphorylation of the insulin receptor (Solomon et al., 2009).

Blood pressure control

Blood pressure is a serious threat to the general health of the community and is a major cause of disability and mortality, and a modest reduction in blood pressure reduces the risk of cardiovascular disease. The terpenic compounds of Citrus medica, including limonene, decrease blood pressure. Limonene and its metabolites have a vasodilation property and thus lower blood pressure.

It also has antioxidant activity with its compounds, such as citral, limonene and Linalool, thus preventing LDL oxidation by preventing plaque formation in the vasculature and thus preventing cardiovascular disease and blood pressure (Bugger, 2008). Due to its prostaglandin-like effects, cardioprotein has an effect on vascular resistance and peripheral vasodilatation, resulting in lowering blood pressure. The product compounds block the blood vessels of the α-adrenergic receptors, reduce the environmental resistance, and ultimately lower blood pressure (Guidline, 1999).

Inhibition of platelet aggregation and increased fibrinolytic activity

One of the most important causes of cardiovascular disease is the formation of blood clots. The thromboxane A2 factor, which is made up of arachidonic acid in the membrane of the platelets, activates and aggregates the platelets. Thus, cardioproteinemia, by reducing platelet aggregation, activates the platelet inhibitor and thereby reduces blood clotting in the vessels and decreases the risk of stroke (Guidline, 1999).

Treatment for atherosclerosis

The gradual deposition of cholesterol (one of the types of blood lipids), other lipids and substances in the internal wall of the arteries leads to the formation of platelets in the wall of the arteries, which leads to tight, rigidity of the walls of the veins. In this case, arteriosclerosis is referred to. Over time, an increase in fat deposits can lead to stenosis and narrowing of the arteries and prevent sufficient blood supply to the tissues. If this happens in the coronary arteries, it can cut or even cut off the blood supply to the heart muscle. In the event that there is not enough blood to the heart muscle, it is called heart ischemia.

Phytoestrogens in cardioprotein can reduce the risk of inflammation and the risk of cardiovascular disease through β-adrenergic receptors. Many scientific evidence suggests that free radicals play an important role in the development and initiation of atherosclerosis. Therefore, the use of Cardi-Ay, which contains high levels of antioxidants, by controlling lipid peroxidation and lipid solubilization, significantly reduces atherosclerosis damage. Flavonoids present in cardiomyopathy also have strong antioxidant properties that improve endothelial function. On the other hand, phenolic compounds have the ability to react directly with some active oxygen groups (such as OH, HOCL) and prevent the oxidation of LDL. Various studies have shown that vitamins such as vitamin E, which are lipid soluble, and vitamin C, have protective effects against the LDL oxidation reaction. Thus, using cardioproteins and increasing the concentration of these vitamins in the body can extent the progression of atherosclerosis decreases. Also, these compounds in the cardioprotective anemia activate the catalase and glutathione reductase enzymes, which prevent anti-oxidative action by preventing the onset of atherosclerosis (Durrington, 2002).

Decrease of triglycerides and LDL, increase of HDL

Compounds of this product through intestinal lipase inhibition in the intestine increase fat and cholesterol in the stool and consequently reduce serum levels of triglyceride, total cholesterol, low density lipoprotein cholesterol (LDL), and very low density lipoprotein cholesterol (VLDL).

Cardi-Ay polyphenols, by sweeping hazardous oxygen species and reactive nitrogen species, reduce the capacity of the athery macrophages to alter LDL, lipid oxidation and peroxidation. In addition, these compounds increase the serum paraoxonase enzyme activity, which causes the ammerger to hydrolyze lipid peroxides in oxidized lipoproteins and in atherosclerotic plaques.

Isoflavones in cardioprotein can reduce the negative effects of chronic inflammation on the health of the cardiovascular system (Droke, 2007). During taking Cardi-Ay, the level of malondialdehyde decreases and the conjunctival DNs levels increase. In other words, due to decreased malondialdehyde, it can be stated that the use of this product reduces the oxidation of cholesterol. Polyphenolic compounds present in this product reduce the oxidation of LDL and reduce platelet aggregation and, consequently, prevention of cardiovascular disease. Cardi-Ay contains carotenoids, vitamin C, folate, folic acid and a high level of methionine and lysine and unsaturated fatty acids.

These antioxidants produce free radicals. B-Carotene has potent antioxidant effects on the elimination of free radicals and lipid antioxidation. Ascorbic acid in this product reduces the radical tocopherol-oxide and restores the activity of collecting free radicals by tocopherol. Cardi-Ay compomemets increase the activity of the lipoprotein lipase enzyme that changes (VDL) to (HDL), resulting in an increase in high cholesterol (HDL) levels. Cardi-Ay also inhibits HIMG-COA reductase enzymes and Squalene epoxidase (the latest enzyme in the pathway for biosynthesis of cholesterol) and thus reduces cholesterol. On the other hand, the compounds found in cardioproteinase inhibit the synthesis of fatty acids by inhibiting the activity of certain lipogenic enzymes such as glucose 6-phosphate dehydrogenase, malic acid dehydrogenase and 4-methyl oxidase (Bhatia, 2003).


  • Bhatia AL, Jain M. Amaranths paniculatus (Linn.) improves learning after radiation stress. J Ethnopharmacol. 2003 Mar; 85(1): 73-9.
  • Bugger H, Boudina S, Hu XX, Tuinei J, Zaha VG, Theobald HA, et al. Type 1 diabetic akita mouse hearts are insulin sensitive but manifest structurally abnormal mitochondria that remain coupled despite increased uncoupling protein 3. Diabetes. 2008 Nov; 57(11):2924-32.
  • Droke E, Hager K, Lerner M, Lightfoot S, Stoecker B, Brackett D. Soy isoflavones avert chronic inflammation-induced bone loss and vascular disease. J Inflamm (Lond) .2007Sep; 4: 17.
  • Durrington PN, Mackness B and. Mackness MI. The hunt for nutritional and pharmacological modulators of paraoxonase. Arterioscler. Thromb. Vasc. Biol. 2002; 22 (8): 1248 - 50.
  • Grande S, Bogani P, de Saizieu A, Schueler G, Galli C, Visioli F. Vasomodulating potential of Mediterranean wild plant extracts. J Agric Food Chem 2004; 52: 5021-6.
  • Guidline Subcommittee. 1999 World Health Organization. Intermational Society of ypertension guidinebfor the management of hypertension. J Hypertens 1999; 17: 151 –83.
  • Hayat SA, Patel B, Khattar RS, Malik RA. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci (Lond). 2004 Dec; 107(6):539-57.
  • Khan A, Safdar M, Khan MM, Khattak KN, Anderson RA. Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes care 2003; 26(12):3215-3218.
  • Kumar G, Sharmila Banu G, Ganesan Murugesan A. Effect of Helicteres isora bark extracts on heart antioxidant status and lipid peroxidation in streptozotocin diabetic rats. J Appl Biomed. 2008; 6: 89-95.
  • Solomon TPJ, Blannin AK. Changes in glucose tolerance and insulin sensitivity following 2 weeks of daily cinnamon ingestion in healthy humans. Eur J Appl Physiol 2009; 105(6):969-976.
  • Tripathi UN, Chandra D. The plant extracts of Momordica charantia and Trigonella foenum-graecum have anti-oxidant and anti-hyperglycemic properties for cardiac tissue during diabetes mellitus. Oxid Med Cell Longev. 2009 Nov-Dec; 2(5):290-6.
  • Voulgari C, Papadogiannis D, Tentolouris N. Diabetic cardiomyopathy: from the athophysiology of the cardiac myocytes to current diagnosis and management strategies. Vasc Health Risk Manag. 2010 Oct; 6:883-903. doi: 10.2147/VHRM.

Get in touch

Our helpline is always open to receive any inquiry or feedback. Please feel free to drop us an email from the form below and we will get back to you as soon as we can.


No. 18, 15th Yasaman, 13th Bozorgmehr,
Bozorgmehr St., Sajad Blvd., Mashhad,
Khorasan Razavi, Iran